Refine by
Neurodegeneration Articles & Analysis
181 news found
Versatile compound shows promise in drug synthesis, metal chelation, antioxidant activity, and moreChangsha, China – May 22, 2025– Hunan Huateng Pharmaceutical Co., Ltd., a leading global supplier of PEG derivatives and pharmaceutical intermediates, is proud to offer high-purity N-Benzylhydroxylamine Hydrochloride (CAS 29601-98-7) to researchers and pharmaceutical developers worldwide. This ...
Creative Proteomics, a leader in proteomics and metabolomics services, has officially launched its innovative Central Carbon Metabolism (CCM) Analysis Service, designed to transform the study of cellular energy dynamics and metabolic pathways in both health and disease. This groundbreaking service arrives at a crucial time when understanding cellular metabolism is essential for advancing ...
Alfa Chemistry is one of the leading chemical manufacturers and suppliers who has been able to maintain its leadership position in the pharmaceutical sector by offering a broad product portfolio that caters to all aspects of the drug creation process. Always innovative and outstanding, Alfa Chemistry now has an extensive range of products within the pharmaceutical field, including PROTAC building ...
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, proudly announces an extensive portfolio of Nervous System Tissue Microarrays designed to support neuroscience research. This comprehensive collection provides researchers with a unique resource to study various neurological conditions and accelerate their investigations into neurological ...
CD Genomics, a prominent leader in the next generation sequencing arena, proudly announce the launch of a groundbreaking 5mC/5hmC sequencing service. This innovative service is poised to empower researchers by providing a deeper insight into epigenetic variations, unlocking the mysteries of epigenetics, and catalyzing pivotal advancements in the realm of life science research and precision ...
In the pursuit of advancing disease research and its treatment, animal cognitive behavior is studied in a wide range of animal species. The innovative multi-type animal cognitive behavioral tests are set to complement disease research methodology, enabling scientists to gain deeper insight into the complexities of cognitive functioning and its implications in various pathological conditions. ...
In today’s fast-paced and stressful society, the prevalence of anxiety and depression has become a significant concern. Emotion-related animal behavior tests aim to provide a good research tool for the study of emotion-associated diseases. Anxiety and depression affect millions of individuals worldwide, leading to a significant burden on public health and impacting overall quality of ...
CD Genomics, a leading biotechnology company specializing in genomics and sequencing, has announced the launch of its advanced Mitochondrial Diseases Panel Sequencing services. This new panel enables rapid and accurate detection of mutations in mitochondrial DNA (mtDNA) that are associated with a wide range of mitochondrial disorders. Mitochondrial diseases are a complex and heterogeneous group ...
At the end of the 19th century, the German scientist Paul Ehrlich began to realize that certain chemicals could have highly specific effects on certain diseases. He began to write about the possibility that a drug could act like a magische kugel—magic bullet—that killed only the organism causing disease, and nothing else. Today, scientists are amassing a new arsenal of ...
$5.5M financing led by Taiho Ventures LLC, with participation of existing investors, including the Series Seed lead, Kizoo Technology Capital GmbH Fresh capital to be employed to get cellvie Series A ready by accelerating the development of the company's technology platform, strengthening the team, and advancing the mitochondria's GMP manufacturing cellvie Inc., a leader in Therapeutic ...
A five-year action plan developed to meet requirements under Section 4 of the Accelerating Access to Critical Therapies for ALS Act. ...
TEL AVIV & WENDELSHEIM, Germany--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG's lead compound anle138b and a related compound, sery433. Anle138b targets pathological alpha-synuclein oligomers and is being evaluated in patients with ...
Lipids are essential to many body functions and serve as the building blocks for living cells. Alfa Chemistry has been an ISO 9001:2015 certified supplier of nearly all forms of lipids and fatty acids and continues to broaden its product lines by adding phospholipids, modified lipids, and functionalized lipids. These lipid molecules are recently added to the already well-established collection of ...
“The issuance of the ‘766 patent supports our continued work aimed at blocking tau self-association to prevent downstream damage associated with neurodegeneration and dementias,” said James Moe, Ph.D., MBA, CEO and Head of Discovery and Strategy at Oligomerix. ...
Our lead compound, OLX-07010, has demonstrated efficacy in several animal models of neurodegeneration and, upon completion of its preclinical program, will start Phase 1 clinical studies in the first half of 2022. ...
The lead candidate has demonstrated efficacy in animal models of tau-mediated neurodegeneration. Preclinical safety studies are completed and Phase 1a clinical studies are planned to initiate in the third quarter of 2022. ...
Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, and Kurve Therapeutics, a next-generation medtech and drug formulation company, today announced positive preclinical study results for intranasal administration of a cell-based oncolytic virus bearing product. The results ...
Oligomerix’s lead candidate has demonstrated efficacy in multiple animal models of tau-mediated neurodegeneration. Phase 1a first-in-human clinical studies are expected to begin in the near term. ...
Eikonoklastes Therapeutics, a preclinical biotech company developing treatments for today’s most challenging diseases, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced a manufacturing partnership that will advance Eikonoklastes’ AAV-based gene therapy, ET-101, into clinical trials for the treatment of patients with ...
Targeting neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s Identified two lead cannabinoid analog compounds for in vivo studies NSERC grant funding supports InMed’s collaborative research projects with Dr. Kumar from University of British Columbia (UBC) VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals ...